CHINA LIFE

China Life edged up today, primarily supported by Citi raising its price target to HKD 36.2. The stock opened at HKD 28.90 in the morning session, declined to HKD 28.50 around 09:57, then recovered steadily to reach HKD 29.28 in the afternoon before closing at HKD 29.20. From a valuation perspective, the stock trades about 19% below its 52-week high of HKD 36.16 reached on February 10, 2026, with a year-to-date gain of just 1.25%. At a PE of 5.03 and PB of 1.22, valuations remain relatively attractive. Recent business developments include a 1.5 billion RMB logistics fund partnership with Mapletree and a new insurance sales framework agreement with CLP&C effective January 1, 2027. However, Q1 results showed revenue declining 10.25% year-over-year and net profit falling 28.31%, reflecting persistent earnings headwinds.

China Life edged up 2% to HKD28.90, buoyed by Citi's target price upgrade to HKD36.2 with reiterated Buy rating and the company's announcement of an extraordinary general meeting today signaling potential corporate actions. On earnings, Q1 2026 achieved net profit of HKD22.1 billion and EPS of HKD0.7823, swinging back from Q4's loss and signaling recovery momentum despite a 28% year-over-year earnings decline; revenue contracted 10.25% year-on-year but showed sequential recovery to HKD61.9 billion. Valuation-wise, the stock trades at compressed multiples of PE 4.98 and PB 1.21, gaining just 0.21% year-to-date and trading 20% below its 52-week high of HKD36.16, hovering slightly above the 20-day moving average of HKD28.22. The company recently inked a new insurance sales framework agreement with CLP effective January 2027, broadening its distribution network. Sector headwinds remain reflected in the earnings contraction year-over-year.

China Life declined around 2.5% today, driven by profit-taking after a stretch of positive catalysts. The stock touched a high of HKD 28.82 in the morning session before retreating to close at HKD 27.94. Recent momentum remains constructive with Citi raising its target price to HKD 36.2, implying roughly 29% upside and reiterating a Buy rating, while UBS issued a positive earnings prewarning and Morgan Stanley maintained an Overweight stance. Q1 earnings showed EPS of HKD 0.78, down 28.39% year-over-year, yet valuations remain compressed at a PE of 4.82 and PB of 1.17. Price-wise, the current level is 22.73% below the 52-week high of HKD 36.16 and down just 3.12% year-to-date, trading notably below the 20-day moving average of HKD 28.09, signaling technical weakness. That said, Q1 revenue declined 10.25% year-over-year, reflecting near-term growth concerns.

China Life rose 0.77% today, climbing to an intraday high of HK$28.94 during the morning session before settling at HK$28.66 at close, primarily driven by better-than-expected 1H26 earnings guidance projecting net profit growth of 2.15-2.35x year-over-year. The positive signal has garnered institutional support, with UBS reiterating its Buy rating and Morgan Stanley maintaining Overweight stance while forecasting new business value to continue outperforming peers. Management confidence was further underscored by the asset management division's net purchase of over RMB 10 billion in a single trading session. Valuation metrics appear attractive: the stock trades at a PE multiple of just 4.94x with a dividend yield of 3.39%, while the share price has pulled back 20.74% from its 52-week high of HK$36.16, offering a relatively reasonable entry point. However, Q1 revenue still declined 10.25% year-over-year with earnings per share down nearly 28%, reflecting ongoing headwinds in the insurance sector.

China Life fell 0.56% to HK$28.44, primarily driven by profit-taking as the strong 1H26 earnings outlook (net profit expected to surge 2.15-2.35 times YoY) had already been largely priced in. While the newly announced insurance sales framework agreement with CLP&C effective January 1, 2027 is constructive, it failed to offset selling pressure. On fundamentals, Q1 revenue of HK$61.858 billion (YoY -10%) and EPS of HK$0.7823 (YoY -28%), though sequentially lower, represent significant recovery from Q4's massive loss. Both Morgan Stanley and UBS maintain positive stances—overweight and buy ratings respectively; supported by a low 4.9x P/E, 3.41% dividend yield, and HK$803.8 billion market value. Positioned 21% below the 52-week high of HK$36.16 and down merely 1.39% year-to-date, the stock faces limited downside risk.